Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st‐line BRAF‐targeted therapy

BRAF‐mutant melanoma patients can theoretically access both immunotherapy and BRAF‐targeted therapy as treatment for metastatic disease. BRAF‐targeted therapy is increasingly used 1st line for poorer prognostic patients, so we wanted to assess realistic expectations of these patients accessing 2nd‐l...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, James, Lucey, Rebecca, Corrie, Pippa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826286/
https://www.ncbi.nlm.nih.gov/pubmed/36114599
http://dx.doi.org/10.1111/pcmr.13067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826286/
https://www.ncbi.nlm.nih.gov/pubmed/36114599
http://dx.doi.org/10.1111/pcmr.13067

Ejemplares similares